DELRAY BEACH, Fla., July 17, 2014 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it has received a new order from a large government contractor for the continued testing and evaluation of PositiveID's M-BAND (Microfluidic Bioagent Autonomous Networked Detector) in support of an existing U.S. government contract. In keeping with contractual obligations the contractor and program have not been named. As a result of this new purchase order, the company has increased its 2014/2015 revenue and backlog (backlog added to revenue recognized) estimate from $3.3 million to $3.5 million, and is reiterating its revenue guidance of $4-10 million through the end of 2015 (2014 and 2015 combined).
"We view this latest purchase order as another validation of not only our technical capabilities, but also our ability to collaborate with large commercial and government partners, while continuing to execute our strategy," stated William J. Caragol, Chairman and CEO of PositiveID. "We are very pleased to continue the testing of our M-BAND units to protect our nation's warfighters and defenders."
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including, without limitation, the likelihood that the Company will generate revenue through the end of 2015 of $4-10 million (2014 and 2015 combined), $3.5 million of which is currently in backlog; the likelihood that testing of the Company's M-BAND units will continue; and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the bio-threat detection and rapid medical testing sectors; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 11, 2014, and 10-Qs filed on May 20, 2014, November 19, 2013, and August 14, 2013, as amended August 19, 2013, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.